Chugai Pharmaceutical Co., Ltd.
4519.T
Below: live stock price for Chugai Pharmaceutical Co., Ltd. (4519.T), a 1-year chart, 8 indicators (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volume), and a compare mode. Add to your portfolio, star to your watchlist, or set a price alert in one place.
Chugai Pharmaceutical Co., Ltd. (4519.T) is a Healthcare company based in Japan. Operating in Drug Manufacturers - General, it employs about 5,104 people. Over the past year 4519.T traded between 5,974 and 10,700 JPY. Trailing P/E sits near 22.29 on a market cap of about 11.23T JPY. It currently yields 1.93% in dividends.
- Prev close
- $42.24
- Volume (24h)
- $133.26M
- Market cap
- $71.29B
- Currency
- USD (native JPY)
Score
65/ 100 · Solid
- Value48
- Quality92
- Momentum32
- Growth59
- Risk71
- Dividend50
- Liquidity100
Composite of public market data. Informational only — not investment advice.
Trend projection
Where the recent trend points if it continues.
- +5 bars
- 43.0309 -0.66%
- +20 bars
- 42.6408 -1.56%
- +60 bars
- 42.4909 -1.90%
- +120 bars
- 42.4854 -1.92%
Linear-regression continuation — not a prediction, not investment advice. ±1σ ≈ 68% range · ±2σ ≈ 95% range: 1σ ≈ ±1.85% per bar.
Interpretation
Composite signals look solid. Strength: balance-sheet liquidity with weakness: momentum. Price sits near the upper third of the recent range, trend is sloping downward.
Descriptive observation — not investment advice.
Score breakdown
Raw values behind each pillar so you can see what the composite is reading.
- Value48/100
Value looks mixed — driven by P/E (22.29).
P/E:22.29P/B:5.37PEG:1.58 - Quality92/100
Quality looks strong — driven by Gross margin (71.46%).
ROE:25.32%ROA:18.73%Profit margin:35.61%Gross margin:71.46% - Momentum32/100
Momentum looks weak — driven by 52w change (-1.81%).
52w change:-1.81% - Growth59/100
Growth looks mixed — driven by Earnings growth (29.10%).
Revenue growth:21.50%Earnings growth:29.10% - Risk71/100
Risk looks solid — driven by Beta (0.56).
Beta:0.56 - Dividend50/100
Dividend looks mixed — driven by Payout ratio (45.08%).
Dividend yield:1.93%Payout ratio:45.08% - Liquidity100/100
Liquidity looks strong — driven by Current ratio (6.39).
Current ratio:6.39Quick ratio:5.02
Derived from public market data — informational, not investment advice.
Price report
How this asset has actually moved over the last 242 days.
Where the price sits between the window low and high.
- Volatility (annualised)
- 40.4%
- Max drawdown
- -42.4%
- Below period high
- -36.2%
- Best day
- +7.44%
- Worst day
- -15.83%
- Up days
- 49%
- Current streak
- 2 up
- Typical day swing
- 2.6%
- Volume vs average
- +9%
Spread of returns. Higher means larger swings in both directions.
Worst peak-to-trough fall inside the window.
Current price against the highest point in the window.
Share of days that closed above the one before.
Average high-to-low spread within a single day.
Last 10 days against the whole window.
Descriptive statistics over past prices — not a forecast and not investment advice.
Reference levels
Fibonacci retracements and extensions across the recent range.
Reference only — not investment advice.
These coordinates describe past-trade clustering, not where to buy or sell. Do your own research before any trade.
Levels derived from: 45.9001 high → 37.9315 low · 60 bars
- ResistanceFib +161.8% extensionnot reached58.7931 USD+35.73% from current
- ResistanceFib +100% extensionnot reached53.8686 USD+24.36% from current
- ResistanceFib +61.8% extensionnot reached50.8246 USD+17.33% from current
- ResistanceFib +27.2% extensionnot reached48.0675 USD+10.97% from current
- ResistanceFib 23.6% retracementtested 8×44.0195 USD+1.62% from current
- Current43.3158 USD
- SupportFib 38.2% retracementNearesttested 10×42.8561 USD-1.06% from current
- SupportFib 50% midpointtested 8×41.9158 USD-3.23% from current
- SupportFib 61.8% retracementtested 3×40.9755 USD-5.40% from current
- SupportFib 78.6% retracementtested 3×39.6368 USD-8.49% from current
- SupportFib −27.2% extensionnot reached35.7641 USD-17.43% from current
- SupportFib −61.8% extensionnot reached33.007 USD-23.80% from current
- SupportFib −100% extensionnot reached29.963 USD-30.83% from current
How to read this
We take the highest and lowest price of the last 60 bars and cut the gap between them at the classic Fibonacci ratios (23.6%, 38.2%, 50%, 61.8%, 78.6%), plus extensions beyond both ends.
“Tested N×” counts how many of those 60 bars actually traded through the level. A level price has crossed many times is one the market has repeatedly agreed on; a level at 0 is pure geometry the price has never reached.
This is a map of where trading has already happened — not a forecast and not a signal. Price moves through these levels all the time.
Financials
- 52w high
- ¥10,700
- 52w low
- ¥5,974
- 52w change
- -1.81%
- Day high
- ¥6,828
- Day low
- ¥6,667
- P/E (TTM)
- 22.29
- Forward P/E
- 28.92
- PEG
- 1.58
- Price / Book
- 5.37
- Beta (5Y)
- 0.56
- Enterprise value
- 10.36T
- EV / Revenue
- 7.32
- EV / EBITDA
- 14.58
- EPS (TTM)
- ¥306.09
- Forward EPS
- ¥235.91
- Dividend yield
- 1.93%
- Dividend rate
- ¥132
- Payout ratio
- 45.08%
- Revenue (TTM)
- 1.41T
- EBITDA
- 710.2B
- Free cash flow
- 212.73B
- Total cash
- 868.99B
- Total debt
- 0
- Current ratio
- 6.39
- Quick ratio
- 5.02
- Profit margin
- 35.61%
- Gross margin
- 71.46%
- Return on assets
- 18.73%
- Return on equity
- 25.32%
- Shares outstanding
- 1.65B
- Float
- 639.38M
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept, an immunosuppressant; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi, a spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company has a collaboration with Phylo, Inc. to deploy an agentic AI platform for biomedical research across its drug discovery workflow. The company was formerly known as Chugai Shinyaku Shokai and changed its name to Chugai Pharmaceutical Co., Ltd. in January 1943. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding AG.
Analyst & Risk
Analysts' consensus via Yahoo Finance — not investment advice.
- Beta (vs S&P 500)
- 0.56
- less volatile
- 52-week change
- -1.81%
- Current ratio
- 6.39
- Quick ratio
- 5.02
- ROE
- 25.32%
- ROA
- 18.73%
- PEG ratio
- 1.58
- EV / Revenue
- 7.32
- EV / EBITDA
- 14.58
- Revenue growth
- 21.50%
- Earnings growth
- 29.10%
- EBITDA
- 710.2B
- Free cash flow
- 212.73B
- Total cash
- 868.99B
- Total debt
- 0
- Insider holdings
- 59.89%
- Institutional
- 19.45%
Related
Other assets in this category.
Learn the terms
Live discussion
Sign in to join the discussion.
- No comments yet. Be the first.